Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis Academic Article uri icon


MeSH Major

  • Erythrocytes
  • Fibrinolytic Agents
  • Plasminogen Activators
  • Recombinant Fusion Proteins
  • Single-Chain Antibodies


  • Chemical coupling to carrier red blood cells (RBCs) converts tissue type plasminogen activator (tPA) from a problematic therapeutic into a safe agent for thromboprophylaxis. The goal of this study was to develop a more clinically relevant recombinant biotherapeutic by fusing a mutant tPA with a single-chain antibody fragment (scFv) with specificity for glycophorin A (GPA) on mouse RBCs. The fusion construct (anti-GPA scFv/PA) bound specifically to mouse but not human RBCs and activated plasminogen; this led to rapid and stable attachment of up to 30,000 copies of anti-GPA scFv/PA per mouse RBC that were thereby endowed with high fibrinolytic activity. Binding of anti-GPA scFv/PA neither caused RBC aggregation, hemolysis, uptake in capillary-rich lungs or in the reticuloendothelial system nor otherwise altered the circulation of RBCs. Over 40% of labeled anti-GPA scFv/PA injected in mice bound to RBC, which markedly prolonged its intravascular circulation and fibrinolytic activity compared with its nontargeted PA counterpart, anti-GPA scFv/PA, but not its nontargeted PA analog, prevented thrombotic occlusion in FeCl(3) models of vascular injury. These results provide proof-of-principle for the development of a recombinant PA variant that binds to circulating RBC and provides thromboprophylaxis by use of a clinically relevant approach.

publication date

  • March 2010



  • Academic Article



  • eng

PubMed Central ID

  • PMC2835436

Digital Object Identifier (DOI)

  • 10.1124/jpet.109.159194

PubMed ID

  • 19952305

Additional Document Info

start page

  • 1022

end page

  • 31


  • 332


  • 3